feedback

Course Director

Jessica Donington, MD
Jessica Donington, MD

The University of Chicago Medicine
Chicago, Illinois

Faculty

Natasha B. Leighl
Natasha B. Leighl, MD, MMSc, FRCPC, FASCO

University of Toronto
Princess Margaret Cancer Centre
Toronto, Ontario

Brendon Stiles
Brendon Stiles, MD

Weill Cornell Medicine/NewYork-Presbyterian Hospital
New York, New York

Accredited by

Medical Learning Institute, Inc.

Activity Details

Credit Types:CME / MOC / CNE
Credit Amount:1.5 Credits
Release Date:2019-Jun-17
Expiration Date:2020-Jun-16
Estimated Time for Completion:90 minutes
Registration Required:No
Cost:Free of Charge

Activity Description and Educational Objectives

New evidence from clinical trials assessing immunotherapies and combinations in lung cancer is emerging at a rapid pace. As a result, the treatment landscape is constantly evolving, and checkpoint inhibitor–based therapeutic approaches are establishing a foothold not only in advanced disease but in earlier stages of lung cancer as well. Immunotherapy has proven to be effective in the context of multimodal therapy in stage III locally advanced NSCLC. This has increased excitement about further expanding the role of this therapeutic approach in earlier stages of lung cancer, including resectable disease. A range of novel single-agent and combination immunotherapeutic approaches are being explored in studies in different settings and populations throughout the disease continuum, and the results are eagerly anticipated. However, many challenges and questions related to the optimal use of immunotherapy in stage III and earlier stages of lung cancer remain. In this activity, based on a recent satellite symposium, an expert panel of two surgeons and a medical oncologist offers practical guidance on how to navigate the rapidly changing and complex immuno-oncology landscape in earlier stages of lung cancer.

Upon completion of this activity, participants will be able to:
  • Describe the mechanisms of action of immune checkpoint inhibitors and other novel cancer immunotherapies and the rationale for using immunotherapy as a component of multimodal therapy in earlier stages of lung cancer
  • Review the present immunotherapy landscape and state of the science in lung cancer, including key approvals/indications in different settings from early-stage to more advanced disease
  • Discuss key clinical trials assessing immunotherapies and immune-based combinations in stage III and earlier stages of lung cancer, including resectable disease, and available data from such trials
  • Determine the best treatment approaches for patients with stage III or earlier lung cancer as part of clinical practice or clinical trials based on the latest evidence, recommendations, patient needs and preferences, and effective multidisciplinary collaboration and coordination of care

Target Audience

This activity has been designed to meet the educational needs of thoracic surgeons, medical oncologists, radiation oncologists, nurses, nurse practitioners, physician assistants, and other clinicians involved in the management of lung cancer.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME/MOC/CNE credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME/MOC/CNE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: June 17, 2019 - June 16, 2020
Time to Complete: 90 minutes

Faculty and Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Other PVI associates who are in a position to have control over the content of this activity, do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/MOC/CNE activity during the past 12 months.

The associates of the Medical Learning Institute, Inc., the accredited provider for this activity, do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/MOC/CNE activity during the past 12 months.

Course Director and Moderator

Jessica Donington, MD
Chief, Section of Thoracic Surgery
The University of Chicago Medicine
Chicago, Illinois

Jessica Donington, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca.
Honorarium from AstraZeneca.

Jessica Donington, MD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: immune checkpoint inhibitors and combinations.

Faculty

Natasha B. Leighl, MD, MMSc, FRCPC, FASCO
Professor, Department of Medicine, University of Toronto
OSI Pharmaceuticals Foundation Chair in Cancer New Drug Development
Thoracic Site Lead, Division of Medical Oncology
Princess Margaret Cancer Centre
Toronto, Ontario

Natasha B. Leighl, MD, MMSc, FRCPC, FASCO, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Bristol-Myers Squibb; F. Hoffmann-La Roche; Lilly; GlaxoSmithKline; Merck Sharp & Dohme (MSD); Nektar; and Pfizer. (Uncompensated). Excovery (Compensated). Canadian Agency for Drugs and Technologies in Health.
Grant/Research Support from Array BioPharma; AstraZeneca; F. Hoffmann-La Roche; and Guardant Health. (Support to Institution).

Natasha B. Leighl, MD, MMSc, FRCPC, FASCO, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: immune checkpoint inhibitors and combinations.

Brendon Stiles, MD
Associate Professor, Department of Cardiothoracic Surgery
Weill Cornell Medicine/NewYork-Presbyterian Hospital
New York, New York

Brendon Stiles, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca and Medtronic.
Other Financial or Material Support from Chair of Board for the Lung Cancer Research Foundation (LCRF). Spouse employed with Pfizer Inc. and Pharmaceutical Product Development, LLC. (PPD) Video Speaker for Medscape.

Brendon Stiles, MD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: immune checkpoint inhibitors and combinations.

Content Reviewers

Julia Rotow, MD, has no financial interests/relationships or affiliations in relation to this activity.

Tracy Greene, MSN, RN, FNP-C, Lead Nurse Planner, has no financial interests/relationships or affiliations in relation to this activity.

Bobbie Perrin, RN, OCN, has no financial interests/relationships or affiliations in relation to this activity.

Medical Directors

Kristin Tomlinson, PhD
PVI, PeerView Institute for Medical Education

Kristin Tomlinson, PhD, has no financial interests/relationships or affiliations in relation to this activity.

Kadrin Wilfong, MD
PVI, PeerView Institute for Medical Education

Kadrin Wilfong, MD, has no financial interests/relationships or affiliations in relation to this activity.

Disclaimer

The information provided at this CME/MOC/CNE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit, and Support

Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

ABIM MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared with ABIM through the ACCME’s Program and Activity Reporting System (PARS). Blinded individual or aggregated participant data may be shared with the funder of the activity.

Nurses

Medical Learning Institute, Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Successful completion of this continuing nursing education activity will be awarded 1.5 contact hour(s).

Providership


This CME/MOC/CNE activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support

This activity is supported by an independent educational grant from AstraZeneca.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

About This CME/MOC/CNE Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

Copyright © 2000-2019, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.